BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback

Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once aga

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 41,000 shares of the

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 45,000 shares of the

BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer ove

BioNTech said on Monday ​that a late-stage ‌trial showed its drug candidate gotistobart ​led to a ​c

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech a

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg

BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Pe

BioNTech and Moderna are no longer generating significant revenue from their coronavirus vaccines. B

BioNTech has not performed well in recent years, as its COVID-19 portfolio has struggled. However, t

BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalan

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the

On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning,

Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, toppin

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum an

BioNTech (BNTX), the mRNA vaccine and oncology developer, pulled the plug on its Phase 2 colorectal-

BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate i

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene c

A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX

BioNTech SE said on Friday it has ​decided to terminate the mid-stage trial ‌of its experimental mRN

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closel

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasda

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closel

Moderna stock is giving back a large chunk of Tuesday's rally. The pullback reopens a question that

Two names built on the same platform have stopped moving together this morning. Moderna (NASDAQ:MRNA

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine,

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vacci

BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its indi

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

https://youtu.be/H_RititNE8U

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price

Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lo

BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 bill

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst conse

BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that its Su

The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lower

https://www.bloomberg.com/news/articles/2026-06-17/biontech-investor-fortsch-says-founders-spinout-r

UBS analyst David Dai upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price ta

Bernstein analyst Jeffrey Walch initiates coverage on BioNTech (NASDAQ:BNTX) with a Market Perfor